Synopsis Risedronate is suggested to be effective for the prevention and treatment of osteoporosis in total hip arthroplasty. The objective of this study is to evaluate the efficiency of risedronate in reducing femoral periprosthetic bone mineral density loss in patients undergoing primary total hip arthroplasty (THA). This week’s “MED FACT” discusses a clinical trial from Journal of Orthopaedic Surgery and Research, “The efficiency of risedronate in reducing bone resorption after total hip arthroplasty: a meta-analysis of randomized control trials at a minimum of 6 months’ follow-up”.
Authors: Liqing Yang Key Takeaways: Risedronate significantly reduced periprosthetic bone resorption around an uncemented femoral stem after total hip arthroplasty. Objective: To determine efficiency of Risedronate in reducing bone resorption Study Type: Randomized controlled trial, Meta-analysis…
